Business
CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions
MONMOUTH JUNCTION, N.J., Sept. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Sept. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb was granted medical device registration by the Brazilian Health Regulatory Agency (ANVISA). CytoSorb is now commercially available in Brazil to treat cytokine storm in cardiac surgery and critical illnesses such as COVID-19 infection and will be distributed by Contatti Medical.\n\n \n \n \n \n \n \n\n \nMr. Alessandro Pallamolla, Chief Executive Officer of Contatti Medical stated, \"Contatti is a well-established company located in southern Brazil, with over 36 years of experience providing excellent solutions to the healthcare market. We could not be happier to partner with CytoSorbents and leverage our strengths in cardiac surgery, organ transplantation, and blood bank management, to help make CytoSorb a success. CytoSorb is an innovative therapy for critical care and cardiac surgery, with huge potential in Brazil, given the high incidence of heart disease and sepsis in the country. In addition, the immediate availability of CytoSorb comes at a very delicate moment during the COVID-19 crisis in Brazil. We welcome this opportunity to work with CytoSorbents and to explore together all of the possibilities in our country.\" \nDr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, \"We are pleased to announce the official registration of CytoSorb in Brazil and the launch of our partnership with Contatti Medical to distribute CytoSorb throughout the country. We are very excited to collaborate with Contatti, whose business focus parallels ours, with an extensive network within hospitals and among physicians in Brazil. Our immediate focus will be to help treat patients with life-threatening complications of COVID-19 infection, with 30,000-40,000 new coronavirus cases a day, and a total of 4.5 million total cases in the country to date, third only to the U.S. and India.\"\nBrazil is the 6th most populous country in the world with a population of 212 million people divided into 5 regions and 27 states. Brazil has the 9th largest global economy with a Gross Domestic Product (GDP) of $1.87 trillion (no...